AIM
CORT icon

Acrospire Investment Management’s Corcept Therapeutics CORT Stock Holding History

Acrospire Investment Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-7,047
Closed -$83K – 314
2017
Q2 		$83K Sell
7,047
-1,166
-14% -$12.7K 0.08% 365
2017
Q1 		$90K Sell
8,213
-24,416
-75% -$214K 0.07% 382
2016
Q4 		$237K Buy
32,629
+9,712
+42% +$76.1K 0.1% 251
2016
Q3 		$149K Sell
22,917
-558
-2% -$3.25K 0.1% 274
2016
Q2 		$128K Buy
23,475
+8,974
+62% +$46.7K 0.1% 275
2016
Q1 		$68K Buy
+14,501
New +$56.5K 0.05% 651

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acrospire Investment Management's CORT Position: Q3 2017 in Review

Acrospire Investment Management sold out of Corcept Therapeutics (CORT) in Q3 2017, closing a stake of 7,047 shares — an estimated $83K sold.

Acrospire Investment Management first reported a position in CORT in Q1 2016 and held it in 6 quarters. The position peaked at $237K in Q4 2016. 189 funds tracked by Wall St. Rank hold CORT as of Q3 2017.

  • Acrospire Investment Management reported no remaining Corcept Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 7,047 Corcept Therapeutics shares in Q3 2017, an estimated $83K.
  • Acrospire Investment Management first reported a position in Corcept Therapeutics in Q1 2016 and held it in 6 quarters.
  • Acrospire Investment Management's Corcept Therapeutics position peaked at $237K in Q4 2016.
  • 189 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.